Susceptibility of Candida albicans isolates from the oral cavities of HIV-positive patients to histatin-5

Journal of Prosthetic Dentistry

Volumn 88, Issue 3, 2002, Pages 263-267

  Nikawa, Hiroki ^a   Jin, Chen ^a   Makihira, Seicho ^a   Hamada, Taizo ^a   Samaranayake, Lakshman P ^b  

^a HIROSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

HISTATIN 5; ANTIFUNGAL AGENT; SALIVA PROTEIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; FUNGUS ISOLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOUTH CAVITY; NONHUMAN; STATISTICAL ANALYSIS; AIDS RELATED COMPLEX; ANALYSIS OF VARIANCE; CANDIDA ALBICANS; COMPARATIVE STUDY; IMMUNOLOGY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; NONPARAMETRIC TEST; SERODIAGNOSIS; THRUSH;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANALYSIS OF VARIANCE; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS, ORAL; FEMALE; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; SALIVARY PROTEINS; STATISTICS, NONPARAMETRIC;

EID: 0036730267     PISSN: 00223913     EISSN: None     Source Type: Journal    
DOI: 10.1067/mpr.2002.127907     Document Type: Article

References (27)

1. Cannon RD, Holmes AR, Mason AB, Monk BC. Oral Candida: clearance, colonization, or candidiasis? J Dent Res 1995;74:1152-61.
2. Green SL. Anaerobic pleuro-pulmonary infections. Postgrad Med 1979; 65:62-6, 68-9, 72-4.
3. Martin BJ, Corlew MM, Wood H, Olson D, Golopol LA, Wingo M, et al. The association of swallowing dysfunction and aspiration pneumonia. Dysphagia 1994;9:1-6.
4. Worthington M. Fetal candida pneumonia in a non-immunosuppressed host. J Infect 1983;7:159-61.
5. Samaranayake LP. Host factors and oral candidosis. In: Samaranayake LP, MacFarlane TW, editors. Oral candidosis. London: Butterworth and Co Ltd; 1990. p. 66-103.
6. Helmerhorst EJ, Reijnders IM, van't Hof W, Simoons-Smit I, Veerman EC, Amerongen AV. Amphotericin B- and fluconazole-resistant Candida spp., Aspergillus fumigatus, and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides. Antimicrob Agents Chemother 1999;43:702-4.
7. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998;11: 382-402.
8. Barchiesi F, Hollis RJ, Del Poeta M, McGough DA, Scalise G, Rinaldi MG, et al. Transmission of fluconazole-resistant Candida albicans between patients with AIDS and oropharyngeal candidiasis documented by pulsed-field gel electrophoresis. Clin Infect Dis 1995;21:561-4.
9. Situ H, Bobek LA. In vitro assessment of antifungal therapeutic potential of salivary histatin-5, two variants of histatin-5, and salivary mucin (MUC7) domain 1. Antimicrob Agents Chemother 2000;44:1485-93.
10. Oppenheim FG, Xu T, McMillian FM, Levitz SM, Diamond RD, Offner GD, et al. Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans. J Biol Chem 1988;263:7472-7.
11. Pollock JJ, Denepitiya L, MacKay BJ, Iacono VJ. Fungistatic and fungicidal activity of human parotid salivary histidine-rich polypeptides on Candida albicans. Infect Immun 1984;44:702-7.
12. Murakami Y, Nagata H, Shizukuishi S, Nakashima K, Okawa T, Takigawa M, et al. Histatin as a synergistic stimulator with epidermal growth factor of rabbit chondrocyte proliferation. Biochem Biophys Res Commun 1994; 198:274-80.
13. Edgerton M, Koshlukova SE, Lo TE, Chrzan BG, Straubinger RM, Raj PA. Candidacidal activity of salivary histatins. Identification of a histatin 5-binding protein on Candida albicans. J Biol Chem 1998;273:20438-47.
14. Nikawa H, Samaranayake LP, Tenovuo J, Pang KM, Hamada T. The fungicidal effect of human lactoferrin on Candida albicans and Candida krusei. Arch Oral Biol 1993;38:1057-63.
15. Nikawa H, Samaranayake LP, Tenovuo J, Hamada T. The effect of antifungal agents on the in vitro susceptibility of Candida albicans to apolactoferrin. Arch Oral Biol 1994;39:921-3.
16. Nikawa H, Samaranayake LP, Hamada T. Modulation of the anti-Candida activity of apo-lactoferrin by dietary sucrose and tunicamycin in vitro. Arch Oral Biol 1995;40:581-4.
17. Tobgi RS, Samaranayake LP, MacFarlane TW. The in vitro susceptibility of Candida species to lysozyme. Oral Microbiol Immunol 1987;3:35-9.
18. Nikawa H, Hayashi S, Nikawa Y, Hamada T, Samaranayake LP. Interactions between denture lining material, protein pellicles and Candida albicans. Arch Oral Biol 1993;38:631-4.
19. Lal K, Santarpia RP 3rd, Xu L, Manssuri F, Pollock JJ. One-step purification of histidine-rich polypeptides form human parotid saliva and determination of anti-candidal activity. Oral Microbiol Immunol 1992;7:44-50.
20. Tsai H, Bobek LA. Human salivary histatin-5 exerts potent fungicidal activity against Cryptococcus neoformans. Biochim Biophys Acta 1997; 1336:367-9.
21. Xu T, Levitz SM, Diamond RD, Oppenheim FG. Anticandidal activity of major human salivary histatins. Infect Immun 1991;59:2549-54.
22. Raj PA, Edgerton M, Levine MJ. Salivary histatin 5: dependence of sequence, chain length, and helical conformation for candidacidal activity. J Biol Chem 1990;265:3898-905.
23. Mandel ID, Barr CE, Turgeon L. Longitudinal study of parotid saliva in HIV-1 infection. J Oral Pathol Med 1992;21:209-13.
24. Sternberg S. The emerging fungal threat. Science 1994;266:1632-4.
25. Silverman S Jr, Migliorati CA, Epstein, JB, Samaranayake LP. Laboratory diagnosis of oral candidosis. In: Samaranayake LP, MacFarlane TW, editors. Oral candidosis. London: Butterworth and Co Ltd; 1990. p. 213-37.
26. Nikawa H, Hamada T. Binding of salivary or serum proteins to Candida albicans in vitro. Arch Oral Biol 1990;35:571-3.
27. Nikawa H, Nishimura H, Yamamoto T, Hamada T, Samaranayake LP. The role of salivary or serum pellicle in the colonization process of Candida albicans on denture acrylic in vitro. Microbial Ecol Health Dis 1996;9:35-48.